Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2007

View Archived Issues

DOV reports positive phase Ib data for its lead TRIP in depression

Recent patents cover novel agents for neurologic disorders

Bayer describes new thrombin inhibitors

Roche and Schering-Plough separately claim novel compounds for obesity and related disordes

PRLX-93936's antitumor activity profiled by Prolexys

Recombinant human IL-18 to be tested in NHL

AnGes submits Naglazyme BLA to Japanese Ministry of Health

Fosaprepitant tolerability, bioequivalency with oral aprepitant explored

Genta announces initiation of Genasense named-patient/compassionte program

Enrollment completed for Pervasis' phase II trial of Vascugel for ESRD

FoldRx and CFFT enter collaboration agreement for cystic fibrosis research

Study finds regadenoson safe in subjects with decreased renal function

Polyphenolic grape extract activity may explain cardiovascular benefits of red wine

Recruitment completed for pSivida phase IIa study of BrachySil

Anti-IL-18 antibody ABT-325 profiled at Abbott

Cardiome Pharma reports second quarter 2007 results

New PI3K inhibitor described by Merck Serono

Second quarter 2007 results reported by Biomarin

Avigen initiates AV-411 clinical development in the U.S.

Metabolic discontinues ACV-1 clinical trial

Arpida closes TLT acquisition

Esprit Pharma acquires Sanctura XR marketing rights

EMEA accepts Santhera's filing of SNT-MC17 for Friedreich's ataxia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...